Abiraterone for Prostate Cancer Not Previously Treated with Hormone Therapy.

Details

Ressource 1Download: nejmoa1702900.pdf (516.71 [Ko])
State: Public
Version: Final published version
Serval ID
serval:BIB_CF2E19F79ACD
Type
Article: article from journal or magazin.
Collection
Publications
Institution
Title
Abiraterone for Prostate Cancer Not Previously Treated with Hormone Therapy.
Journal
The New England journal of medicine
Author(s)
James N.D., de Bono J.S., Spears M.R., Clarke N.W., Mason M.D., Dearnaley D.P., Ritchie AWS, Amos C.L., Gilson C., Jones R.J., Matheson D., Millman R., Attard G., Chowdhury S., Cross W.R., Gillessen S., Parker C.C., Russell J.M., Berthold D.R., Brawley C., Adab F., Aung S., Birtle A.J., Bowen J., Brock S., Chakraborti P., Ferguson C., Gale J., Gray E., Hingorani M., Hoskin P.J., Lester J.F., Malik Z.I., McKinna F., McPhail N., Money-Kyrle J., O'Sullivan J., Parikh O., Protheroe A., Robinson A., Srihari N.N., Thomas C., Wagstaff J., Wylie J., Zarkar A., Parmar MKB, Sydes M.R.
Working group(s)
STAMPEDE Investigators
ISSN
1533-4406 (Electronic)
ISSN-L
0028-4793
Publication state
Published
Issued date
27/07/2017
Peer-reviewed
Oui
Volume
377
Number
4
Pages
338-351
Language
english
Notes
Publication types: Clinical Trial, Phase II ; Clinical Trial, Phase III ; Journal Article ; Multicenter Study ; Randomized Controlled Trial ; Research Support, Non-U.S. Gov't
Publication Status: ppublish
Abstract
Abiraterone acetate plus prednisolone improves survival in men with relapsed prostate cancer. We assessed the effect of this combination in men starting long-term androgen-deprivation therapy (ADT), using a multigroup, multistage trial design.
We randomly assigned patients in a 1:1 ratio to receive ADT alone or ADT plus abiraterone acetate (1000 mg daily) and prednisolone (5 mg daily) (combination therapy). Local radiotherapy was mandated for patients with node-negative, nonmetastatic disease and encouraged for those with positive nodes. For patients with nonmetastatic disease with no radiotherapy planned and for patients with metastatic disease, treatment continued until radiologic, clinical, or prostate-specific antigen (PSA) progression; otherwise, treatment was to continue for 2 years or until any type of progression, whichever came first. The primary outcome measure was overall survival. The intermediate primary outcome was failure-free survival (treatment failure was defined as radiologic, clinical, or PSA progression or death from prostate cancer).
A total of 1917 patients underwent randomization from November 2011 through January 2014. The median age was 67 years, and the median PSA level was 53 ng per milliliter. A total of 52% of the patients had metastatic disease, 20% had node-positive or node-indeterminate nonmetastatic disease, and 28% had node-negative, nonmetastatic disease; 95% had newly diagnosed disease. The median follow-up was 40 months. There were 184 deaths in the combination group as compared with 262 in the ADT-alone group (hazard ratio, 0.63; 95% confidence interval [CI], 0.52 to 0.76; P<0.001); the hazard ratio was 0.75 in patients with nonmetastatic disease and 0.61 in those with metastatic disease. There were 248 treatment-failure events in the combination group as compared with 535 in the ADT-alone group (hazard ratio, 0.29; 95% CI, 0.25 to 0.34; P<0.001); the hazard ratio was 0.21 in patients with nonmetastatic disease and 0.31 in those with metastatic disease. Grade 3 to 5 adverse events occurred in 47% of the patients in the combination group (with nine grade 5 events) and in 33% of the patients in the ADT-alone group (with three grade 5 events).
Among men with locally advanced or metastatic prostate cancer, ADT plus abiraterone and prednisolone was associated with significantly higher rates of overall and failure-free survival than ADT alone. (Funded by Cancer Research U.K. and others; STAMPEDE ClinicalTrials.gov number, NCT00268476 , and Current Controlled Trials number, ISRCTN78818544 .).

Keywords
Abiraterone Acetate/administration & dosage, Abiraterone Acetate/adverse effects, Adult, Aged, Aged, 80 and over, Androgen Antagonists/administration & dosage, Androgen Antagonists/adverse effects, Antineoplastic Combined Chemotherapy Protocols/adverse effects, Antineoplastic Combined Chemotherapy Protocols/therapeutic use, Humans, Male, Middle Aged, Neoplasm Metastasis/drug therapy, Neoplasm Recurrence, Local/drug therapy, Prednisolone/administration & dosage, Prednisolone/adverse effects, Prostate-Specific Antigen/blood, Prostatic Neoplasms/drug therapy, Prostatic Neoplasms/mortality, Prostatic Neoplasms/radiotherapy, Prostatic Neoplasms/surgery, Steroid 17-alpha-Hydroxylase/antagonists & inhibitors, Survival Analysis
Pubmed
Web of science
Create date
19/06/2017 7:29
Last modification date
20/08/2019 15:49
Usage data